SCHEMBL3872192

SCHEMBL3872192

O=C1CCc2ccccc2N1C1CCN(CCC(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.71

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 10/20 0.59
OPRM1 P35372 9/20 0.59
OPRK1 P41145 6/20 0.59
MTR Q99707 1/20 0.57
KCNA3 P22001 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1864606 0.89 OPRM1 (0.66) OPRL1OPRM1OPRK1MTR
SCHEMBL3881201 0.86 OPRM1 (0.56) OPRL1OPRM1OPRK1
SCHEMBL3869637 0.80 OPRM1 (0.61) OPRL1OPRM1OPRK1
SCHEMBL2675276 0.79 OPRM1 (0.70) OPRL1OPRM1OPRK1
SCHEMBL27597318 0.78 OPRM1 (0.58) OPRL1OPRM1OPRK1
SCHEMBL3878013 0.78 OPRM1 (0.80) OPRL1OPRM1OPRK1
SCHEMBL8200492 0.77 MTR (0.67) OPRL1OPRM1OPRK1MTRKCNA3
SCHEMBL3871435 0.76 OPRL1 (0.68) OPRL1OPRM1OPRK1
Hydrochloric Acid SCHEMBL8202341 0.76 MTR (0.66) OPRL1OPRM1OPRK1MTRKCNA3
SCHEMBL18309848 0.76 OPRM1 (0.57) OPRL1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253727-A1 NOCICEPTIN ANALOGS PURDUE PHARMA L.P. (US) 2009-10-08 US claimed
EP-1997818-A2 Quinolinone derivatives and their use to treat pain EURO-CELTIQUE S.A. (LU) 2008-12-03 EP claimed
EP-1379252-A4 NOCICEPTIN ANALOGS EURO CELTIQUE SA (LU) 2005-11-02 EP claimed
EP-1379252-A2 NOCICEPTIN ANALOGS Euro-Celtique S.A. (LU) 2004-01-14 EP claimed
US-20030013874-A1 Nociceptin analogs PURDUE PHARMA L.P 2003-01-16 US claimed
WO-2002085291-A2 NOCICEPTIN ANALOGS EURO-CELTIQUE, S.A. (LU) 2002-10-31 WO claimed
US-20090253727-A1 NOCICEPTIN ANALOGS PURDUE PHARMA L.P. (US) 2009-10-08 US disclosed
US-7563809-B2 Nociceptin analogs PURDUE PHARMA, L.P. (US) 2009-07-21 US disclosed
EP-1997818-A2 Quinolinone derivatives and their use to treat pain EURO-CELTIQUE S.A. (LU) 2008-12-03 EP disclosed
US-20050148580-A1 Nociceptin analogs PURDUE PHARMA L.P 2005-07-07 US disclosed
US-6861421-B2 Nociceptin analogs EURO-CELTIQUE S.A (LU) 2005-03-01 US disclosed
US-20030013874-A1 Nociceptin analogs PURDUE PHARMA L.P 2003-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148580-A1 Nociceptin analogs OPRL1, OPRK1, NPBWR1 OPRL1 1/4885OPRM1 4/4885OPRK1 2/4885
US-20030013874-A1 Nociceptin analogs OPRL1, OPRK1, NPBWR1 OPRL1 1/4885OPRM1 5/4885OPRK1 2/4885
US-20090253727-A1 NOCICEPTIN ANALOGS OPRL1, NPBWR1, OPRK1 OPRL1 1/4885OPRM1 5/4885OPRK1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.